Rafael Holdings, Inc. (RFL) - 10-Q Summary
Business Context and Reporting Period
Period: Quarterly report for the three and nine months ended April 30, 2025.
Business Overview: Rafael Holdings is a holding company focused on clinical and early-stage pharmaceuticals. Key subsidiaries include Cyclo Therapeutics (wholly-owned), LipoMedix (95% owned), Cornerstone Pharmaceuticals (67% owned), Day Three Labs (84% owned), and Rafael Medical Devices (73% owned).
Strategic Shift: Following the March 25, 2025, merger with Cyclo Therapeutics, the Company has designated Trappsol® Cyclo® (for Niemann-Pick Disease Type C1) as its lead clinical program. Management is currently evaluating its portfolio to focus resources on this core asset.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended April 30, 2025 |
Nine Months Ended April 30, 2025 |
Nine Months Ended April 30, 2024 |
|---|---|---|---|
| Total Revenue | $362 | $567 | $472 |
| Net Loss (Consolidated) | $(4,051) | $(18,589) | $(60,149) |
| Net Loss Attributable to RFL | $(4,779) | $(18,426) | $(29,942) |
| Loss Per Share (Basic & Diluted) | $(0.19) | $(0.73) | $(1.26) |
| Cash and Cash Equivalents | $37,936 | $37,936 | $7,436 |
| Total Assets | $108,096 | $108,096 | $96,832 |
| Total Liabilities | $23,578 | $23,578 | $10,574 |
| Working Capital | $31,413 | $31,413 | $64,988 |
Segment Performance (Nine Months 2025):
- Healthcare: Revenue of $243k (driven by Cyclo product sales); Operating Loss of $(12.6M).
- Infusion Technology: Revenue of $93k; Operating Loss of $(3.8M), including a $3.1M goodwill impairment charge.
- Real Estate: Revenue of $231k; Operating Loss of $(13k).
Material Changes vs. Prior Period
- Revenue Growth: Nine-month revenue increased 20% to $567k, primarily due to new product revenue from Cyclo Therapeutics ($243k) following the March 2025 merger.
- Improved Net Loss: Consolidated net loss decreased significantly to $(18.6M) for the nine months ended April 30, 2025, compared to $(60.1M) in the prior year. This improvement is largely due to the absence of a one-time $89.9M in-process research and development (IPR&D) expense recorded in the prior year related to the Cornerstone acquisition.
- Goodwill Impairment: The Company recorded a $3.1M impairment charge related to the Infusion Technology segment (Day Three Labs) due to operational reductions and layoffs.
- Investment Activity: The Company sold its available-for-sale securities portfolio in November 2024, resulting in a net loss of $16k, to reallocate assets. Cash balances increased by $35.3M year-over-year due to these sales and proceeds from hedge fund withdrawals.
- Debt Forgiveness: As part of the Cyclo Merger, $21.5M in outstanding principal and accrued interest on Cyclo Convertible Notes were forgiven and included in the purchase consideration.
Guidance, Outlook, and Risks
Outlook: Management intends to fund the Transport NPC Phase 3 clinical trial for Trappsol® Cyclo® to its 48-week interim analysis, with results expected shortly after the filing date. The Company will determine whether to file a New Drug Application (NDA) based on these results.
Liquidity: With $37.9M in cash and cash equivalents, the Company expects sufficient liquidity to meet obligations for at least the next 12 months.
Subsequent Events:
- Leadership Change: William Conkling resigned as CEO effective May 31, 2025. Howard S. Jonas was elected CEO effective June 1, 2025.
- Rights Offering: On June 4, 2025, the Company closed a rights offering and backstop private placement, raising approximately $24.9M in net proceeds.
Risks and Contingencies:
- Customer Concentration: Two major customers accounted for 77% of total revenues in the third quarter of fiscal 2025.
- Manufacturing Dependence: Reliance on third-party suppliers for Trappsol® Cyclo® manufacturing; any disruption could delay clinical trials.
- Tax Attributes: The impact of the Cyclo acquisition on the utilization of Net Operating Losses (NOLs) under Section 382 remains uncertain pending analysis.
Investor Verification Checklist
- Cyclo Merger Accounting: Verify the final purchase price allocation and the treatment of the $21.5M debt forgiveness and $30M IPR&D asset.
- Phase 3 Trial Results: Monitor the upcoming 48-week interim analysis results for Trappsol® Cyclo® to assess the probability of an NDA filing.
- Capital Raise Utilization: Track the deployment of the $24.9M raised in the June 2025 rights offering to ensure alignment with the Cyclo clinical trial funding plan.
- Customer Retention: Assess the stability of the two major customers representing 77% of recent revenue.
- Goodwill Valuation: Review the assumptions used in the $3.1M impairment test for the Infusion Technology segment to gauge future impairment risks.